SEHK:1177Pharmaceuticals
Sino Biopharmaceutical (SEHK:1177) Advances Pipeline As Valuation Signals Stay Mixed
Sino Biopharmaceutical (SEHK:1177) is back in focus after China’s regulators approved Peceleganan Spray and accepted a new drug application for tecotabart vedotin, LM-302. These are two pipeline milestones in infection control and advanced gastric cancer.
See our latest analysis for Sino Biopharmaceutical.
Despite the drug pipeline progress, Sino Biopharmaceutical’s share price tells a mixed story. The HK$4.62 close reflects a 1-day share price return of 4.76% and a 7-day gain of 8.45%, set...